BCLI
BRAINSTORM CELL THERAPEUTICS INC.
Key Financials
Operating Income
$-9953000
↑ 14.9%
Net Income
$-10307000
↑ 11.3%
EPS (Diluted)
$-1.11
↑ 51.9%
Total Liabilities
$11.0M
↑ 14.7%
Shareholders' Equity
$-9985000.00
↓ 28.6%
Total Assets
$1.0M
↓ 44.2%
Cash & Equivalents
$29000.00
↓ 84.5%
Operating Cash Flow
$-6975000.00
↑ 23.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-K | 3/31/2026 | View on SEC |
| 8-K | 3/31/2026 | View on SEC |
| 8-K | 2/27/2026 | View on SEC |
| 8-K | 2/13/2026 | View on SEC |
| 8-K | 1/9/2026 | View on SEC |
| 10-Q | 11/14/2025 | View on SEC |
| 8-K | 11/14/2025 | View on SEC |
| 8-K | 11/6/2025 | View on SEC |
| 25-NSE | 10/9/2025 | View on SEC |
| 10-Q | 8/14/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BCLI |
| Company Name | BRAINSTORM CELL THERAPEUTICS INC. |
| CIK | 1137883 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | OTC |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 201-488-0460 |